Hepatocellular carcinoma (HCC) is one of the leading cancer-related deaths worldwide. Recently, studies for HCC treatment are focused on cancer immunotherapy, particularly cancer vaccines, to complete and assist other therapies. TPX2 is a microtubule-associated protein necessary for cell division; therefore, alteration in its expression, especially up regulation, is associated with several human carcinomas such as HCC. In this study, immunoinformatics tools were used to design a rational multi-epitope T vaccine against TPX2 in HCC. Cytotoxic T lymphocytes (CTL) and Helper T lymphocytes (HTL) epitopes were predicted and Maltose-binding protein (MBP) was added to the construct as an adjuvant. Evaluation of vaccine properties was indicated that our construct is stable and immunogenic enough to induce relevant responses besides not being allergic. After predicting the tertiary structure and energy minimization, protein-protein docking and molecular dynamics were performed to calculate the free energy and stability of possible interactions between the vaccine and tolllike receptor 4 (TLR4) to assure that simultaneous complementary responses would be activated by our construct. Finally, Codon optimization and in silico cloning were performed to ensure the vaccine expression efficiency in the desired host.
Introduction
Among cancer-related death worldwide liver cancer was the second leading cause of 788,000 death in 2015 (WHO 2015) . Hepatocellular carcinoma (HCC) is the most prevalent primary liver cancer which is commonly associated with cirrhosis. Factors lead to cirrhosis can be divided into two categories: viral factors and non-viral factors.
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The first, includes hepatitis B virus (HBV) and hepatitis C virus (HCV), and the second includes factors such as Alcohol and lifestyle (obesity) (Gurakar et al. 2001; Ringelhan et al. 2018) . Traditional HCC treatments comprises surgery (i.e., liver resection and transplantation), radioactive seed implantation, trans-arterial chemoembolization (TACE) and radiofrequency ablation (RFA) do not completely eliminate the residual of cancer cells and even may lead to metastasis (Qin 2012) .
Current studies are focused on cancer immunotherapy, especially cancer vaccines, since they can activate cytotoxic T lymphocytes (CTL); therefore, it may be possible to eliminate cancerous cells without damaging the healthy ones (Xie et al. 2018) .
Cell division needs a microtubule-associated protein known as targeting protein for Xklp-2 (TPX2) (Aref et al. 2014) . Depletion of TPX2 can increase G2/M transition and rise cell polyploidy and genomic instability which in return induces multi-nucleation and DNA damage in HCC cells (Hsu et al. 2017 ). TPX2 expression is tightly controlled during cell cycle progression and its alterations have been reported to be associated with human carcinogenesis. TPX2 overexpression is reported in lung, cervical, bladder, esophageal, liver, and pancreatic cancer, (Liang et al. 2016) . Peptides derived from TPX2 can be recognized by CTLs, so in HCC replication cycle, TPX2 can be produced and recognized by CTLs, then HCC cells can be killed by activating CTLs (Aref et al. 2014 ) so it would be a rational candidate for designing anti-hepatocellular cancer vaccine.
Triggering Helper T lymphocytes (HTL) is a crucial step for the induction of CTL response (Pandey et al. 2018) . Instead of using the whole protein as an antigen, only the immunogenic parts, i.e., epitopes, can be used for designing an immunogenic construct with ideal features (Soria-Guerra et al. 2015) . In the present study, we used immunoinformatics tools to design a multi-epitope T vaccine including CTL and HTL epitopes to activate both cytotoxic and helper T lymphocytes. The ability of the vaccine construct in induction of the immune responses was also evaluated through multiple in silico assessments such as identifying its antigenicity and allergenicity, stability, and its capability in binding to immune receptors through protein-protein docking simulations.
Methods

The Main Steps in the Current Study
The main steps of designing the desired vaccine are shown in Fig. 1 .
Prediction of T Cell Epitopes
Complete amino acid sequences of Targeting protein for Xklp2 (UniProt ID: Q9ULW0) consists of 747 amino acids and Maltose/maltodextrin-binding periplasmic protein (UniProt ID: P0AEX9) consists of 396 amino acids were obtained from UniProt (http://www.expas y.org/unipr ot).
In order to predict CTL epitopes for TPX2 several databases including Rankpep (Reche et al. 2004) , IEDB (Kim et al. 2012) , MHCPred (Guan et al. 2003) and Propred-I (Singh and Raghava 2003) were used. For evaluating the immunogenicity, these epitopes were submitted in IEDB MHC-I immunogenicity prediction module and the epitopes with highest scores that can induce CTL response were chosen. The HLA-A*02:01 was chosen for the super type (Huang et al. 2016) . For predicting HTL epitopes for TPX2, Fig. 1 The summarized flowchart of designing multi-epitope T vaccine process IEDB MHC-II epitope prediction module and NetMHCIIpan method were used. The HLA-DRB1*11:03 allele was chosen while the rest of the parameters were default (Varzi et al. 2016) . The epitopes were sorted by their percentile rank. Lower percentile rank shows more affinity for binding to HTL receptor. Top five epitopes were selected with less percentile rank.
IFNepitope server (http://crdd.osdd.net/ragha va/ifnep itope /predi ct.php) were used for evaluating the ability of selected HTL epitopes for inducing INF-γ production, IFN-γ versus other cytokine was chosen as a model of prediction while the rest of the parameters were as the default.
Designing the Multi-epitope T Construct and Its Improvement
CTL and HTL epitopes were fused by maximum immunogenic capability together. For inducing innate immune response as well as adaptive immune responses an adjuvant should be added to the construct. Maltose-binding protein (MBP) not only has intrinsic adjuvant-like properties (Zhao et al. 2011 ) but also adding it at the N-or C-terminus of the protein can facilitate the purification process, (Terpe 2003; Fang et al. 2014) . MBP was linked to N-terminal of the vaccine construct using EAAAK linker while HTL epitopes were linked together by the sequence of KFER. CTL epitopes were also linked together using the sequence of AK (Nezafat et al. 2015) .
Antigenicity and Allergenicity Prediction
ANTIGENpro (http://scrat ch.prote omics .ics.uci.edu/) and VaxiJen (0.4% threshold) (http://www.ddg-pharm fac.net/ vaxij en/VaxiJ en/VaxiJ en.html) servers were used for antigenicity and allergenicity evaluation of final vaccine candidate. ANTIGENpro can classify proteins in the antigenic or non-antiganic group by using SVM and VaxiJen Prediction of antigen is alignment-free and based on various physiochemical properties of protein. AllerTOP v. 2.0 server (http://www.ddg-pharm fac.net/Aller TOP/) was used for the vaccine's allergenicity prediction.
Evaluation of Physicochemical Characteristics of the Vaccine
ProtParam server (https ://web.expas y.org/protp aram/) was used for evaluating physicochemical characteristic of the designed vaccine such as molecular weight, theoretical pI, instability index, aliphatic index, and grand average of hydropathicity (GRAVY). This server is an online tool which can calculate different physicochemical characteristic on the basis of pK values of different amino acids.
Secondary and Tertiary Structure Prediction, Validation, and Energy Minimization
Secondary structure of the vaccine was predicted using GOR4 server (https ://npsa-prabi .ibcp.fr/cgi-bin/npsa_autom at.pl?page=/NPSA/npsa_gor4.html).
Tertiary structure of the vaccine construct was predicted using I-TASSER server (https ://zhang lab.ccmb.med.umich .edu/I-TASSE R/). I-TASSER works based on multiplethreading alignments and iterative template fragment assembly simulations to provide the most accurate structure (Zhang 2008) . For estimating the quality of predicted structure, the confident score (C-score) was used; higher C-score indicates higher confidence of the model. While TM-score and root mean square deviation (RMSD) are known standards for measuring the structural similarity between protein structures; lower values show high resolution and better fits of the model (Wu et al. 2007 ). The ProSA-web online server (https ://prosa .servi ces.came.sbg.ac.at/prosa .php) was used to screen potential errors. The calculated z-score defines the accuracy of the model. Ramachandran plot of the RAM-PAGE server (http://mordr ed.bioc.cam.ac.uk/~rappe r/rampa ge.php) performed and obtained to define stereochemical quality of the final model.
Protein-Protein Docking of the Vaccine with TLR4
The tertiary structures of vaccine construct and TLR4 (PDB ID: 3FXI) as a receptor of the attached adjuvant (Jie et al. 2018 ) was prepared by Chimera 1.11.2. Protein-protein interactions were analyzed using HEX 8.0.0 docking software. The predicted tertiary structure of the vaccine candidate was experienced energy minimization by SPDBV 4.10 with Gromos96 force field before docking. The total free binding energy of interaction measured by regarding shape and electrostatics correlation type (Ghoorah et al. 2013 ). The solution was set to 1000, final search to 25, and other parameters were kept unchanged.
MD Simulation of Vaccine-TLR4 Complex
To determine the stability of Vaccine-TLR4 complex Molecular dynamics (MD) simulation was performed using Gromacs v4.6.5. Vaccine-TLR4 complex from docking process was used as an input in order to understand interaction between vaccine and receptor. In this study GROMOS96 54A7 force field and the particle mesh Ewald summation method were used. According to the Vaccine-TLR4 complex shape, a cubic box was used as the simulation box. In the next step, system equilibration was performed under NVT and NPT ensembles for 100 ps. MD simulation was performed for a time duration of 45 ns. Finally, the root mean square deviation (RMSD) and root mean square fluctuation (RMSF) were evaluated to check the standard deviation and fluctuation of the protein backbone.
Codon Optimization and In Silico Cloning
For optimizing the Codon Usage of vaccine candidate for E. coli, K12 strain as the host, JCAT (http://www.jcat.de/) was used, (Proux and Dreyfus 2008; Juhas et al. 2014 ). For in silico cloning of the optimized vaccine candidate sequence in pET28a (+), XhoI and NdeI restriction sites were placed by using SnapGene tool which can simulate restriction cloning.
Results
Selected CTL and HTL Epitopes
Cytotoxic T lymphocytes are able to kill cancerous cells. For this purpose, we need immunogenic CTL epitopes which can induce CTL response (Martínez-Lostao et al. 2015) . In order to predict CTL epitopes of TPX2 several servers were used. 739 epitopes from Rankpep 739 from IEDB 515 from MHCPred and top ten epitopes from Propred-I with 9 mer length were obtained. The top 4 consensus epitopes among mentioned databases with higher IEDB MHC-I immunogenicity scores were selected for constructing the final vaccine candidate (Table 1A) . Top 10 CTL epitopes predicted by different servers and their immunogenicity score are listed in supplementary Table 1. For predicting HTL epitopes for TPX2, IEDB MHC-II epitope prediction tool was used. Top four epitopes which had less percentile rank and IC50 values with 15 mer length were selected. (Table 1B) . Then for evaluating the ability to produce INF-γ for final epitopes IFNepitope server was used, and the result for all the epitopes was positive which shows they can activate Th1 and induce the production of INF-γ (Table 1C) . Top 10 predicted HTL epitopes and their score from the IFNepitope server are listed in supplementary Table 2 .
Designing Multi-epitope T Construct
The final construct with 556 amino acids includes 5 CTL and 5 HTL epitopes accompanied by MBP sequence added to its N-terminal. All used linkers sequences are shown in Fig. 2a .
Antigenicity and Allergenicity Evaluation
Antigenicity of the vaccine was predicted by ANTIGENpro and VaxiJen. The scores were 0.80 and 0.43 respectively, which confirm the antigenicity of the vaccine construct, .
Allergenicity of the vaccine was predicted by AllerTOP v. 2.0 server and recognized as non-allergen. 
Physicochemical Characteristics Evaluation of the Final Vaccine
For evaluating physicochemical characteristics of the final vaccine ProtParam server was used. According to the data obtained from the server, the molecular weight of the vaccine candidate was 60.94 kDa; predicted pI was 8.62; and evaluated half-life was shown that the construct is stable. Evaluated aliphatic index was 88.83 which indicates that the vaccine is thermostable. GRAVY was calculated as − 0.219 demonstrating the hydrophilic nature of vaccine. The instability index score was 32.04, which classifies the vaccine as stable (Ali et al. 2017 ).
Secondary and Tertiary Structure Prediction, Validation, and Energy Minimization
The secondary structure of the vaccine construct was predicted using GOR4 web tool. The result indicates that the secondary structure of the vaccine contains 43.88% random coil, 43.17% alpha helix, and 12.95% extended strands (Fig. 2b) .
Among predicted five models of I-TASSER, first model with the highest C-score = − 1.2, TM-score = 0.56 ± 0.15 and RMSD = 10.4 ± 4.6 Å was chosen as the best model (Fig. 2c) .
The z-score obtained from ProSA-web before and after minimization by SPDBV 4.10 was − 11.2 and − 11.27 respectively (Fig. 3a) showing the reliability of the final construct in resembling native proteins. According to Ramachandran plot before minimization, 83.6% of residues were in the favored region, 12.8% in the allowed region and 3.6% in outlier region while the values were improved by 85.6%, 11.2%, and 3.2% respectively after minimization (Fig. 3b) .
Protein-Protein Docking of the Vaccine with TLR4
Protein-protein docking was used for evaluating the interaction between vaccine and TLR4. The estimated binding energy and pose of interaction was two crucial factors in this analysis. The pose of interaction is shown in (Fig. 4a) with − 15601.8 as the resulted binding energy that shows the possibility of interaction between our designed vaccine and TLR4 which improves other complementary inflammatory responses against desired antigen.
MD Simulation of Vaccine-TLR4 Complex
To evaluate physical movements for the docked complex at the microscopic level a MD simulation was performed using Gromacs v4.6.5 with a GROMOS96 54A7 force field. The RMSD for TLR4 and the vaccine was evaluated during the stimulation time (Fig. 5) . The RMSD plot showed a considerably increase with high degree of fluctuations from 5 to 5.1 nm until 20 ns. After 20 ns it stayed fairly constant at about 5.1 nm for the rest of the simulation time. These changes indicate that the vaccine attempts for finding the best position with respect to its receptor. As the plot shows, after 20 ns from beginning of the simulation it is remained almost constant which demonstrates that vaccine and receptor became stable (Fig. 5) .
In addition, RMSF of all residue for vaccine and its receptor was evaluated which shows the time average of RMSD for each residue. Both TLR4 and vaccine showed a small degree of fluctuations during the period (Fig. 6 ). This mild fluctuations in amino acid side chains indicates that interaction between vaccine and receptor is uninterrupted. Thus, the Vaccine-TLR4 complex is stable.
Codon Optimization and In Silico Cloning
In order to reach the maximum level of expression in (E. coli) k12 strain, the DNA sequence of the vaccine was optimized by Java Codon Adaptation Tool (JCAT). The CAI for the optimized vaccine sequence was 1 which is Fig. 3 ProSA-web Z-score plot and Ramachandran plot before and after minimization. a Z-score before and after minimization (the modelled construct shown as black spot). b The improvement of the final construct through minimization visualized by Ramachandran plot ideal, and GC content was 50 which is also in the perfect range (30-70%) . After adding restriction sites of XhoI and NdeI in the optimized sequence, it was cloned in pET28a(+) (Novagen et al. 2003) using SnapGene tool (Fig. 4b) , ; 
Discussion
Worldwide, about 10% of all deaths-in adults-is associated with HCC. Unfortunately, HCC is often diagnosed at late stages. It also may lead to metastasis because of the lack of proper treating procedures (Hepatocellular Carcinoma 2018) . Hence, it is important to find new therapies for solving this severe problem. Recently, studies for HCC treatment are focused on cancer immunotherapy especially cancer vaccines. Unlike traditional vaccines which prevent a certain disease, cancer vaccines are designed to treat existing disease (Lee et al. 2018) . Among various types of vaccines, synthetic peptide vaccines are highly specific and easy to produce (Disis and Cheever 1998) . Whether a vaccine is successful or not highly depends on the tumor antigen that is targeted by the vaccine. The overexpressed self-antigens, as the name indicates, are overexpressed in tumors, while their presence is low but detectable in normal cells. These antigens induce immune responses only against cancerous cells and leave normal ones unharmed, in other words, they do not provoke autoimmunity, (Bright et al. 2014; Jäger et al. 2001) .
In this study we have designed an anti-HCC peptide vaccine based on TPX2 that is included in overexpressed self-antigens group as well as in several human carcinomas. With reference to Chao-Wen Hsu et al., TPX2 is overexpressed in HCC, hence counts as a potential target for immunotherapy against it, (Hsu et al. 2017; Liang et al. 2016 ).
An appropriate synthetic peptide cancer vaccine should be able to induce CTL responses in order to kill the cancerous cells, which require cytokines that are produced by TH cells (Kalams and Walker 1998) . Therefore, it needs to induce both CTL and HTL responses, according to that we tried to predict CTL and HTL epitopes using several immunoinformatic databases. Nowadays immunoinformatic can play a crucial role in designing a cancer vaccine by providing efficient methods for finding a potential candidate for immunotherapy by compering epitopes to find the best candidate based on MHC-binding affinity of the epitopes which are capable to induce a strong immune response (DeLuca and Blasczyk 2007) . Reports indicate that experimental vaccine discovery and development takes approximately 10-20 years and cost of hundreds of million US dollars. While with the help of immunoinformatic tools we can save in time and cost (Pronker et al. 2013) .
After predicting CTL and HTL epitopes, those with less percentile rank which show higher binding affinity were selected. Also, the immunogenicity of the epitopes was evaluated and the result was satisfying.
Cancerous cells may suppress the immune response by producing factors such as (IL-10, TGF, VEGF, and etc.) thus escaping from immune system. To surmount the problem, adjuvants would be added to vaccine construct for generating CTLs which are capable of overcoming the suppressive mechanisms (Singh and Salnikova 2015) . So, we considered it and applied it to our design and MBP sequence was added to N-terminal as an adjuvant to avoid the immune escape mechanisms. We chose MBP as an adjuvant not only because it is able to increase the immunogenicity of the construct but also it can facilitate the expression and purification process of recombinant protein in E. coli, by one-step purification using affinity chromatography (cross-linked amylose), (Terpe 2003; Jie et al. 2018) .
The results for antigenicity and allergenicity of the vaccine construct showed that this vaccine is able to induce a strong immune response while it was known as non-allergen and safe to use. Physicochemical characteristics of the vaccine showed that it is hydrophilic and its structure is stable. The result for thermostability was also satisfying.
The validity and stability of the interaction between vaccine and receptor (TLR4) were evaluated by molecular docking and molecular dynamics simulations. Finally, codon optimization and in silico cloning was performed to ensure the efficiency of expression of the vaccine in appropriate host.
However, for future use of this vaccine in vivo study need to be done for evaluating the immune response against HCC in the real condition. All in all, immunotherapies like monoclonal antibodies, CAR T-cell therapy, checkpoint inhibitors and cancer vaccines are less toxic than chemotherapeutic agent but they may have some side effects so they need further evaluation (Friend and Schiller 2017) .
